Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
2-CHLORODEOXYADENOSINE (2-CDA) FOR AIDS-ASSOCIATED NON-HODGKIN'S LYMPHOMA (NHL). A PHASE I STUDY (MEETING ABSTRACT)
Proc Annu Meet Am Soc Clin Oncol; 10:A12 1991. Unique Identifier : AIDSLINE ICDB/91671494 Kahn J; Kaplan L; Northfelt D; Piro L; Beutler E; Carson D; Abrams D; Volberding P; San Francisco General Hosp., San Francisco, CA 94110
Abstract:
Ten patients with AIDS-associated NHL were treated with 2-CDA in a Phase I dose escalation study. All subjects had histologic diagnosis of high grade B-cell lymphoma, including small noncleaved (3), immunoblastic (3), large cell (2), Burkitt's (1), and unclassified (1). All subjects had Stage IV disease. Nine subjects relapsed after prior chemotherapy and one was previously untreated. Five subjects had an antecedent AIDS diagnosis including 2 with Kaposi's sarcoma (KS), 2 with P carinii pneumonia (PCP), and one with both KS and PCP. The mean CD4+ cell count was 0.049 x 10(9)/L. 2-CDA was administered by 7-day continuous infusion; patients received from 1 to 3 cycles of 2-CDA. Two subjects achieved partial responses and one subject achieved a minimal response. All subjects died with progressive disease. Results by dose level are shown in a table. Toxicity was minimal. Myelosuppression developed in one subject with a transient grade 4 neutropenia that resolved with stopping the infusion. Low-grade fevers were common and superficial phlebitis was observed at the site of infusion. There were no CNS or renal toxicities noted. 2-CDA has activity against AIDS-associated NHL in subjects with refractory disease. It is well tolerated with minimal side effects. The unique mechanism of action of the drug combined with its low toxicity makes it an appealing drug to add to standard chemotherapy for this disease.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Drug Evaluation Human Lymphoma, Non-Hodgkin's/*DRUG THERAPY/ETIOLOGY Pneumonia, Pneumocystis carinii/ETIOLOGY Sarcoma, Kaposi's/*DRUG THERAPY/ETIOLOGY 2-Chloroadenosine/ADVERSE EFFECTS/*THERAPEUTIC USE ABSTRACT CLINICAL TRIAL 910930
M9190736
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
